The introduction of enzalutamide and abiraterone has led to improvement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short period in many patients. In the present study, we developed enzalutamide resistant prostate cancer cells in an Furthermore, the combination of indomethacin and enzalutamide resulted in significant inhibition of enzalutamide-resistant tumor growth. These results suggest that AKR1C3 activation is a critical resistance mechanism associated with enzalutamide resistance, targeting intracrine androgens and AKR1C3 will overcome enzalutamide resistance and improve survival of advanced prostate cancer patients.
Introduction
Targeting androgen signaling via androgen deprivation therapy has been the mainstay of clinical interventions in prostate cancer (PCa). While initially effective, the majority of men experience only transient benefit and relapse with castrate-resistant prostate cancer (CRPC), which is currently incurable. Enzalutamide, a second-generation antiandrogen, was recently approved for the treatment of castration resistant prostate cancer (CRPC) in patients. Despite these advances that provide temporary respite, resistance to enzalutamide occurs frequently and the mechanisms that contribute to resistance are still rudimentary and are under intense investigation. Several potential mechanisms of resistance have been revealed such as AR variants expression (1-3), IL6-Stat3-AR axis activation (4), AR F876L mutation (5, 6) and glucocorticoid receptor (GR) overexpression (7, 8).
Intratumoral androgen biosynthesis has been well characterized as a mechanism of CRPC (9-12), but its role in enzalutamide resistance is yet to be understood. Clinical reports have shown that patients treated with enzalutamide have elevated testosterone levels in the bone marrow (13, 14) . A cascade of enzymes is involved in the biosynthesis of intratumoral androgens, including CYP17A1, HSD3B and AKR1C3. A gain of function mutation in HSD3B1 (N367T) has been identified in CRPC patients recently and was postulated to confer resistance to enzalutamide (15, 16) . Aldo-keto reductase family 1 member C3 (AKR1C3) is a multi-functional enzyme and is one of the most important genes involved in androgen synthesis and metabolism.
AKR1C3 facilitates the conversion of weak androgens androstenedione (A' dione) and 5 α-androstanedione (5α-dione) to the more active androgens testosterone and DHT respectively (17, 18) . It catalyzes conversion of steroids and modulates trans-activation of steroid receptors. Author Manuscript Published OnlineFirst on February 3, 2015; DOI: 10.1158/0008-5472.CAN- Elevated expression of AKR1C3 has been associated with PCa progression and aggressiveness (19, 20) . The role of AKR1C3 in enzalutamide resistant prostate cancer is unknown.
In the present study, we developed PCa cell lines resistant to enzalutamide and found that intracrine androgen synthesis is activated in enzalutamide resistant prostate cancer cells.
Activation of one of the important steroidogenic enzymes, AKR1C3, was identified as a critical mechanism that confers resistance to enzalutamide. Inhibition of AKR1C3 activity using either shRNA or indomethacin resensitized enzalutamide resistant PCa cells to enzalutamide.
Furthermore, the combination of indomethacin and enzalutamide resulted in significant inhibition of enzalutamide-resistant PCa xenograft tumor growth. Author Manuscript Published OnlineFirst on February 3, 2015; DOI: 10.1158/0008-5472.CAN- were purchased from Sigma. Cells resistant to enzalutamide were referred to as C4-2B MDVR (C4-2B enzalutamide resistant) as described previously (2) . All cells were maintained at 37°C in a humidified incubator with 5% carbon dioxide.
Materials and Methods

Reagents and Cell Culture
Sample preparation and analysis of steroids
The steroid extraction and analysis has been described previously (21). Briefly, 50 million C4-2B parental and C4-2B MDVR cells were cultured in serum-and phenol red-free RPMI1640 medium for 5 days, then cells were suspended in 4 mL of a 1:1 water/ methanol mixture. The suspension was homogenized, and the resulting homogenate was cooled on ice. The precipitated material was removed by centrifuging at high speed for 5 min, and the supernatant was removed and evaporated in a SpeedVac (Labconco Inc.) followed by lyophilizer (Labconco Inc.). The residue was suspended in 150 μL of CH3OH/H2O (1:1), filtered through a 0.2 μm ultracentrifuge filter (Millipore inc.) and subjected to UPLC/MS-MS analysis. Samples were run in duplicate during UPLC-MS/MS analysis. Samples were placed in an Acquity sample manager which was cooled to 8 °C to preserve the analytes. Pure standards were used to optimize the UPLC-MS/MS conditions prior to sample analysis. Also, the standard mixture was run before the first sample to prevent errors due to matrix effect and day-to-day instrument variations. In addition, immediately after the initial standard and before the first sample, two spiked samples were run to calibrate for the drift in the retention time of all analytes due to the matrix effect.
After standard and spiked sample runs, blank was injected to wash the injector and remove carry over effect. All experiments were performed on a Waters Xevo-TQ triple quadruple mass spectrometer (Milford, MA, USA) and MS and MS/MS spectra were recorded using Electro Spray Ionization (ESI) in positive ion (PI) and negative ion (NI) mode, capillary voltage of 3.0 kV, extractor cone voltage of 3 V and detector voltage of 650 V. Cone gas flow was set at 50 L/h and desolvation gas flow was maintained at 600 L/h. Source temperature and desolvation temperatures were set at 150 and 350 °C, respectively. The collision energy was varied to optimize daughter ions. The acquisition range was 20-500 Da. Analytical separations were conducted on the UPLC system using an Acquity UPLC HSS T3 1.8 µm 1 X 150 mm analytical column kept at 50°C and at a flow rate of 0.15 ml/min. The gradient started with 100% A (0.1% formic acid in H2O) and 0% B (0.1% formic acid in CH3CN), after 2min, changed to 80% A over 2 min, then 45% A over 5min, followed by 20% A in 2min. Finally it was changed over 1 min to original 100% A, resulting in a total separation time of 15 min. The elutions from the UPLC column were introduced to the mass spectrometer and resulting data were analyzed and processed using MassLynx 4.1 software.
UPLC-MS/MS analysis of steroid metabolites
cDNA microarray analysis
The microarray analysis has been described previously (22) . Briefly, twenty-four hours after plating of 5 × 10 5 C4-2B parental and C4-2B MDVR cells, total RNA was isolated using TRIzol Reagent (Invitrogen) and purified with Eppendorf phase-lock-gel tube. RNA quality of all samples was tested by RNA electrophoresis to ensure RNA integrity. Samples were analyzed by the Genomics Shared Resource (UC Davis Medical Center, Sacramento, CA) using the Affymetrix Human Gene 1.0 ST array. The data was analyzed by Subio platform and Gene Set Enrichment Analysis (GSEA) (23) . Microarray data has been deposited in GEO with the accession number GSE64143. 
Western blot analysis
Cellular protein extracts were resolved on SDS-PAGE and proteins were transferred to nitrocellulose membranes. After blocking for 1 hour at room temperature in 5% milk in (1500 cells/dish) in 100 mm dishes for 14 days, the medium was changed every 3 days; LNCaPneo or LNCaP-AKR1C3 cells were treated with DMSO or 10 μM enzalutamide in media containing 10% complete FBS, cells were plated at equal density (10000 cells/dish) in 100 mm dishes for 28 days, the colonies were rinsed with PBS before staining with 0.5% crystal violet/4% formaldehyde for 30 min and the numbers of colonies were counted.
Real-Time quantitative RT-PCR
Total RNAs were extracted using TriZOL reagent (Invitrogen). cDNAs were prepared after digestion with RNase-free RQ1 DNase (Promega). The cDNAs were subjected to real-time and 5′-ttttccagaggctcttcttcgt-3′ (reverse); CYP17A1, 5′-gggcggcctcaaatgg-3′ (forward) and 5′-cagcgaaggcgaaggcgataccctta-3′ (reverse); HSD17B3, 5′-tgggacagtgggcagtga-3′
(forward) and 5′-cgagtacgctttcccaattcc-3′ (reverse); SRD5A1, 5′-acgggcatcggtgcttaat-3′
(forward) and 5′-ccaacagtggcataggctttc-3′ (reverse); and Actin, 5′-agaactggcccttcttggagg-3′ (forward) and 5′-gtttttatgttcctctatggg-3′ (reverse). 
Measurement of PSA
PSA levels were measured in sera from C4-2B parental or C4-2B MDVR tumor bearing mice using PSA ELISA Kit (KA0208, Abnova, Inc., Walnut, CA) according to the manufacturer's instructions.
In vivo tumorigenesis assay
C4-2B parental or C4-2B MDVR cells (4 million) were mixed with matrigel (1:1) and injected into the prostates of 6-7 week male SCID mice. When the serum PSA level reached 5 ng/ml, mice were randomized into two groups (4 mice in each group) and treated as follows: (1) CWR22Rv1 cells (4 million) were mixed with matrigel (1:1) and injected subcutaneously into the flanks of 6-7 week male SCID mice. Tumor-bearing mice (tumor volume around 50-100 mm3) were randomized into four groups (5 mice in each group) and treated as follows: (1) vehicle control (5% Tween 80 and 5% ethanol in PBS, i.p.), (2) 
Statistical Analysis
All data are presented as means ± standard deviation of the mean (SD). Statistical analyses were performed with Microsoft Excel analysis tools. Differences between individual groups were analyzed by one-way analysis of variance (ANOVA) followed by the Scheffé procedure for comparison of means. p < 0.05 was considered statistically significant.
Results
Identification of AKR1C3 activation in enzalutamide resistant prostate cancer cells
In our previous study, we generated enzalutamide resistant prostate cancer cells, named C4-2B MDVR, by chronic culture of C4-2B cells in media containing enzalutamide (2) higher levels of AKR1C3 compared to C4-2B parental tumors. We performed data-mining using the Oncomine and GEO data bases to compare the expression of AKR1C3 in normal prostate and prostate cancer. Primary prostate cancer and normal prostate express similar AKR1C3 levels in two independent prostate datasets, while AKR1C3 was significantly elevated in metastatic prostate cancer in GEO datasets (Fig.3C) , which is consistent with the previous reports (29, 30).
We further examined the correlation between AKR1C3 and prostate cancer disease progression.
As shown in Fig.3D , AKR1C3 was significantly correlated with Gleason score and recurrence status in prostate cancer patients in two independent prostate datasets in Oncomine. Collectively, these results demonstrate that AKR1C3 is highly expressed in late stage prostate cancer. (Fig.4C) .
The steroidogenic enzymes involved in androgen synthesis and metabolism are illustrated in Fig.   4D , bold arrows and bold font indicate upregulation in enzalutamide resistant prostate cancer cells compared to C4-2B parental cells (Fig.4D) Having demonstrated that AKR1C3 is upregulated in enzalutamide resistant prostate cancer cells and in late stage prostate cancer patients, we next examined whether AKR1C3 could confer resistance to enzalutamide. We found that AKR1C3 was sufficient to confer resistance to enzalutamide in prostate cancer cells. CWR22Rv1 cells or C4-2B MDVR cells were transiently transfected with control shRNA or AKR1C3 shRNA following treatment with enzalutamide for three days. As shown in Fig.5A and B, CWR22Rv1 and C4-2B MDVR cells are resistant to enzalutamide, while knock down of AKR1C3 expression by two independent shRNAs (#561 and #694) restored their sensitivity to enzalutamide. The down regulation of AKR1C3 by shRNA was confirmed by western blot (Fig.5C ). We also generated LNCaP cells stably expressing AKR1C3 (LNCaP-AKR1C3) to test whether exogenous expression of AKR1C3 induces enzalutamide resistance. LNCaP-AKR1C3 and LNCaP-neo vector control cells were treated with different concentrations of enzalutamide for 48 hours and cell numbers were counted. As shown in Fig.5D , LNCaP-AKR1C3 cells exhibited greater resistance to enzalutamide than LNCaP-neo cells. These results were also confirmed by clonogenic ability assay. LNCaP-AKR1C3 cells showed significantly more clonogenic ability than the control LNCaP-neo cells in response to enzalutamide treatment (Fig.5E, F) . Collectively, these results demonstrate that overexpression of AKR1C3 confers resistance to enzalutamide, while down regulation of AKR1C3 resensitizes enzalutamide resistant prostate cancer cells to enzalutamide treatment.
Indomethacin, an inhibitor of AKR1C3 activity, overcomes enzalutamide resistance
Indomethacin, a non-steroidal anti-inflammatory drug (NSAID) used for reducing fever, pain and inflammation, has been shown to be able to inhibit AKR1C3 activity (9, 31, 32). To further examine the role of AKR1C3 in enzalutamide resistance, we used indomethacin to hinder AKR1C3 activation and examined the effects on the response of PCa cells to enzalutamide Immunohistochemical staining of Ki67 showed that cell proliferation was significantly inhibited by indomethacin, and further inhibited by the combination treatment (Fig.6D) . Collectively, these results suggest that inhibition of AKR1C3 by indomethacin reduced enzalutamide-resistant tumor growth, and that combination of enzalutamide with indomethacin further reduced the tumor growth of enzalutamide-resistant prostate cancer. These results indicate that inhibition of AKR1C3 by indomethacin potentiates the cell killing effect of enzalutamide.
Discussion
The second generation androgen antagonist enzalutamide represents an improvement in therapy options for late stage metastatic CRPC (33, 34) . However, the initial responders develop Co-targeting AKR1C3 will provide proof-of-concept experiments to overcome resistance and achieve durable responses in men with second-generation antiandrogen treatment.
Intracrine androgen biosynthesis has been well characterized as a mechanism of CRPC (9-12, 28). Many enzymes are involved in androgen synthesis, including CYP17A1, AKR1C3 and HSD3B. CYP17A1 can be inhibited by abiraterone in clinical treatments (37, 38) . AKR1C3 is a steroidogenic enzyme involved in steroid biosynthesis and mediates the last step of testosterone biosynthesis from androstenedione. It catalyzes conversion of steroids and modulates transactivation of steroid receptors. Elevated expression of AKR1C3 has been associated with PCa progression and aggressiveness (19, 20) . AKR1C3 has also been identified as an AR co-activator (39) . In this study, we used gene enrichment analysis to compare enzalutamide resistant cells to enzalutamide sensitive cells, and found that the steroid biosynthesis genes were highly enriched Indomethacin also has the ability to inhibit PSA and ERG protein expression and decreased testosterone and DHT levels in relapsed VCaP xenograft tumors (9). In the present study, we CYP11B2  UGT1A1  ABCA1  CYP3A5  CUBN  SULT1A1  AKR1C2  SORL1  HSD17B1  AKR1B10  SRD5A3  LGMN  APOL1  CYP17A1  FDXR  INSIG2  LSS  GC  SLX1A-SULT1A3  VLDLR  RDH11  UGT1A1  AKR1C1  CYP11B1  HSD17B14  AKR1C3  CYP7B1  CYP2E1  CYP2C9  SULT1A2  HSD3B1   C4-2B  parental   C4-2B  MDVR   Up regulate   C4-2B  parental   HDLBP  CYP39A1  UGT2B17  APOF  STS  SREBF1  CYP11A1  MSMO1  UGT2B15  HSD17B6  DHCR24  LDLR  SRD5A1  INSIG1   Down regulate   C4-2B  MDVR   -5  0  5  10  15  20   GC  AKR1C3  AKR1C2  SORL1  AKR1C1  HSD3B1  CYP7B1  HSD17B14  FDXR  ABCA1  CYP3A5  CYP2E1  UGT1A1  SULT1A3  CYP11B2  INSIG2  VLDLR  HSD17B1  SRD5A3  AKR1B10  UGT1A1  LSS  LGMN  SULT1A2  APOL1  RDH11  SULT1A1  CUBN  CYP17A1  CYP11B1  CYP2C9  UGT2B15  SRD5A1  INSIG1  HSD17B6  LDLR  MSMO1  DHCR24  CYP11A1  HDLBP  APOF  STS  SREBF1  UGT2B17  CYP39A1 Fold Change H/E
